Buffers – Navigating New Demands On Downstream Raw Materials

Published on:
May 27, 2021

The COVID-19 pandemic has put unusual pressures on the supply and demand of raw materials required for the production and purification of biologics. A specific concern for the biomanufacturing industry is the availability of materials that make up essential buffer components.
Buffers maintain defined conditions that help stabilize proteins through production, purification, formulation, and storage so their composition is important.

In March of 2021, Angela Linderholm, Jennifer Bratt, and Steven Chamow of Chamow & Associates, an Alira Health company, with S. Anne Montgomery co-authored a Q&A style article on topics related to buffer supply.

The article was included as part of an eBook, produced by BioProcess International, addressing the various concerns surrounding the issues of access to raw materials and the impact shortages will have downstream. In the article, several questions about maintaining sustainable relationships between consumers and suppliers, alternative energy sources, and contingency planning were posed to industry experts Laura Kaepplinger and Adi Kleinman. Their responses provide insight into the approaches that the industry is taking to mitigate risk and minimize production impact.

Read the full article, the BioProcess International eBook, “Buffers, navigating new demands on downstream raw materials” by Robert Shaw, Angela Linderholm, Jennifer Bratt, and Steven Chamow.

Related news

Due Diligence Research & Development
Publications August 18, 2021
Infographic: Indication Prioritization and Pre-Commercial Value Assessment
Download our infographic on Indication Prioritization and Pre-Commercial Value Assessment.
Research & Development
Events August 8, 2021
Event: BioProcess International
Join Alira Health at BioProcess International on September 20-23, 2021.
Pharma Research & Development
Publications August 2, 2021
Infographic: Prioritization Strategy of R&D Targets for Biotech Company
Download our infographic on Prioritization Strategy of R&D Targets for Biotech Company
Research & Development
Publications June 9, 2021
EU Supply Integrity Guidelines
Check out Alira Health's latest publication, “EU Supply Integrity Guidelines”. In the document, best practices for European distribution and supply integrity management are highlighted(...)
Research & Development
Publications April 26, 2021
Recombinant Human Polyclonal Antibodies to Treat Disease
Congratulations to Alira Health’s Steven Chamow, PhD, Senior Vice President, CMC and founder of Chamow & Associates, and to Bryan Monroe and Chuck Olson, Senior Consultants, on their(...)
Research & Development
News March 15, 2021
Alira Health Welcomes Nikole Siegmund, Vice President, Preclinical
BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, is pleased to announce that Nikole Siegmund has joined the firm(...)
Research & Development
Publications March 9, 2021
A Primer on Potency Assays for Release of Biologics
A key criterion in determining the quality of a biologic product is whether it has maintained its biological activity or “potency.”

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.